Abstract: Disclosed herein are a pharmaceutical formulation with high stability and dissolution, and a method for preparing the pharmaceutical formulation. The pharmaceutical formulation comprises a pharmacologically active substance, a solvent, a solubilizer, a surfactant, an antioxidant, and an adsorbent. According to the pharmaceutical formulation and the method, the pharmacologically active substance is mixed with the solvent, the solubilizer agent and the surfactant for improving the solubility of the pharmacologically active substance to obtain an amorphous liquid or semi-solid state, the antioxidant is melted together with the mixture to solve poor chemical stability of the pharmacologically active substance in an amorphous or liquid state, and the adsorbent is strongly adsorbed to the molten mixture so as to be transformed into a powder form so that the resulting molecules are reconstituted into very tiny crystal forms within the adsorbent to ensure chemical stability.

Abstract: The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function.

Abstract: Methods comprising administering to the subject apigenin, an apigenin derivative, apigenin and at least one apigenin derivative, or a combination of apigenin derivatives are provided for treating inflammation in a subject in need of the same.

Abstract: The present invention is a topical skin preparation for treatment of fungal infections of the skin and nails. The preparation comprises triacetin in combination with one or more antifungal agents. In a preferred form, the preparation comprises a combination of the antifungal agents tolnaftate and grisiofulvin are used in combination with triacetin. The concentrations of these constituents are 40 to 50% concentration triacetin, 30 to 50% acetone, 0.5-3.0% concentration tolnaftate and 0.5-4.0% concentration grisiofulvin, in one preferred embodiment. Other compounds, such as ethyl alcohol, acetone, amino acids such as n-acetylcysteine, and herbal additives may also be added to the preparation. Further, other antifungal agents such as nystatin, clortimazole, econazole, ketoconazole, miconazole, solconazole, oxiconizole, naftifine, terbinafine, and butenafine, for example, may be substituted for the antifungal agents tolnaftate and grisiofulvin.

Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, compositions containing such compounds and the uses of such compounds as antiparasitic agents.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R1, R1?, R2, R3, R4, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

Abstract: The present invention relates to benzoyl-substituted serineamides of the formula I in which the variables R1 to R11 are as defined in the description, and to their agriculturally useful salts, to processes and intermediates for their preparation, and to the use of these compounds or of compositions comprising these compounds for controlling unwanted plants.

Abstract: The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis.

Abstract: The present invention provides an oil agent having water solubility and oil solubility, as well as suppressed stickiness when applied to skin to exhibit excellent feeling of use, and also provides a lubricating agent, a moisturizing agent and an external preparation containing said oil agent. The oil agent of the present invention comprises a dibasic acid ester compound of general formula I: wherein R1 is an alkylene group having a carbon number of 2-4, which may be mono- or poly substituted, R2 and R3 are, independently of each other, an alkyl group having a carbon number of 1-4, which may be mono- or poly substituted, n and m are, independently of each other, an integer of 0-4 with m+n?1 (provided that the cases wherein both of R2 and R3 are an ethyl group and both of n and m are 1 are excluded).

Abstract: Process for the treatment of, e.g., visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing, in a physiologically acceptable medium, at least 5% by weight of one or more surfactants comprising at least one alkyl chain having from 6 to 16 carbon atoms.

Abstract: A stable consumable emulsion, comprising at least 50% water, 0.2 to 3 wt % of an oil comprising at least 12 wt % of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt % food-grade phospholipid emulsifier is provided which provides noticeable improvements in skin when consumed regularly.

Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.

Abstract: An in vitro culture and/or fertilization medium containing N-acetylcysteine amide (NAC amide) reduces or prevents oxidative stress and free radical formation that contribute to the cellular damage and eventual demise of sperm, oocytes and embryos that are cultured, fertilized and maintained in vitro. The NAC amide-containing medium composition for in vitro culture and fertilization is suitable for use in the culture of oocytes, in the culture and development of early embryos, in the preparation or culture of sperm, and in the pre-treatment of oocytes or sperm. The NAC amide-containing composition supports the growth of viable embryos until blastocyst stage.

Abstract: A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol.

Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.

Abstract: This invention relates to a novel fluorene derivative having a characteristic structure in which guanidino group or the like functional group is linked to the fluorene structure via carbonyl group, or a salt thereof. The compound of the invention has an advantage in that it has high affinity for serotonin receptor subtypes, particularly for 5-HT2B receptor and 5-HT7 receptor, and shows excellent pharmacological effects in comparison with the conventional compounds which have only one of the antagonistic activities of 5-HT2B receptor and 5-HT7 receptor, this is useful as a prophylactic antimigraine agent having high safety and excellent effect.

Abstract: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Abstract: Pentafluorosulfanylbenzoylguanidines of the formula I and II in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.

Abstract: Compounds of formula (I) and their use as fragrance ingredients wherein R is selected from methyl, ethyl, propyl, isopropyl, methoxy and ethoxy; R is hydrogen or methyl; and n is 0 or 1.

Abstract: Selective norepinephrine reuptake inhibitors are used to treat tic disorders.

Abstract: The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.

Abstract: The invention relates generally to the use of N-substituted dopamine derivatives for the treatment of diseases and disorders that involve abnormal lipid peroxidation. This method comprises the administration of a pharmaceutically effective amount of N-acetyldopamine derivatives or N-alkyldopamine derivatives and a pharmaceutically acceptable carrier for treating an animal or human suffering abnormal lipid peroxidation. The N-acetyldopamine derivative or N-alkyldopamine derivatives may be administered alone or in combination with N-acetylserotonin (NAS) to inhibit lipid peroxidation.

Abstract: A method for inhibiting or blocking molecular generating and/or inducing functions of molecules using an inhibitory or blocking agent of the formula: wherein R1-6 are as defined herein.

Abstract: There is provided a method for altering the distribution of body mass by altering the distribution of body mass by decreasing overall percentage fat and/or increasing the proportion of lean mass to fat mass comprising administering to a subject one or more compounds having the ability to alter body mass composition and/or ACE inhibiting activity or a physiologically acceptable derivative or prodrug thereof.

Abstract: The present invention relates to pigments comprising a substrate and, applied thereto, an iron-containing coating comprising metallic iron, process for the preparation of the pigments according to the invention, and the use thereof.

Abstract: The invention relates to formulations of agrochemical compounds formulated as water emulsifiable granules and combined with boron containing fertilisers in the spray tank, to a process for the production of such formulations and to their use as novel, advantageous formulations of crop protection agents.

Abstract: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.

Abstract: The non-invasive administration of many active ingredients fails with efflux pumps which sharply reduce the active ingredient absorption on mucous membranes. According to the invention, the active ingredient absorption on mucous membranes can be drastically improved by using dosages containing glutathione and/or compounds comprising numerous thiol groups, in addition to the active ingredient(s). Forms of administration such as matrix tablets, capsules, eye drops, or microparticles, containing the cited combination of active ingredients and auxiliary substances, can be used.

Abstract: Copolymers comprising: (a) 60 to 99% by weight of at least one monomer selected from the group consisting of N-vinyllactams, N-vinylamides, and mixtures thereof; (1) 1 to 40% by weight of at least one monomer selected from the group consisting of vinyl esters of aliphatic branched C8-C30-carboxylic acids; (c) 0 to 30% by weight of vinyl acetate; and (d) 0 to 39% by weight of at least one additional free-radically copolymnerizable monomer; wherein the % by weight content of components (a), (b), (c) and (d) totals 100%, and with the proviso that the total amount of component (b) and component (c) combined is 1 to 40% by weight based on the copolymer, are described along with methods of using such copolymers to solubilize substances which are insoluble in water, substances which are only sparingly soluble in water, and combinations thereof.

Abstract: Surfactant systems are provided that, upon contact with an oil, can produce a Windsor Type III middle phase microemulsion at a total surfactant concentration of 1.5% to 1.0% or less based on the weight of water in the surfactant system, without the need for a cosolvent or linking molecule. The microemulsions can have a separation time less than about 2 hours and even less than about 15 minutes.

Abstract: The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed are methods for inhibiting or inducing apoptosis and for treatment of a pathological condition by administering to a mammal a therapeutically effective amount of a compound that inhibits or increases the dephosphorylation of a histone deacetylase by a myosin phosphatase or inhibits or increases the binding of a histone deacetylase to a myosin phosphatase.

Abstract: A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.

Abstract: Genes associated with Type II Diabetes Mellitus (T2DM) are identified and screening methods to identify chemical compounds that act on those targets for the treatment of T2DM or its associated pathologies are discussed. The use of EP3 antagonist was found to affect blood glucose levels in mice fed a high-fat diet and made insulin deficient by streptozocin injection.

Abstract: A process for the production of liquid hydrocarbons by the Fischer-Tropsch process comprises a step a) for generating a synthesis gas, a step b) for Fischer-Tropsch synthesis, a step c) for condensing the gaseous effluent obtained during step b), a step d) for separating the effluent condensed during step c) to obtain a gaseous effluent enriched in carbon monoxide and hydrogen, and a step e) for recycling at least a portion of the enriched gaseous effluent obtained during step d) to the Fischer-Tropsch synthesis step b), characterized in that: 1) two molar ratio of concentrations, A1 and A2, are determined between the hydrogen and the carbon monoxide (H2/CO), A1 being the value of said ratio in the supply to the synthesis step b), and A2 being the value of said ratio in any one of the gaseous effluents obtained during steps b) to e); 2) comparing ratios A1 and A2; and 3) adjusting the concentrations of hydrogen and/or carbon monoxide in the synthesis gas to keep the difference between the two ratios A1 and A

Abstract: A method of operating a volume-filling structure, comprising sensing an impact event and expanding the volume-filling structure from a non-expanded state to an expanded state upon the sensed impact event. The volume-filling structure comprises an open celled material, a first end cap connected to one end of the open celled material and a second end cap connected to a second end of the open celled material. The volume-filling structure further includes an activation mechanism regulating expansion of the open celled material from the non-expanded state to expanded state in response to an activation signal, and the activation mechanism includes an actuator interfaced with the end caps. Embodiments may include triggering a pneumatic device to force the second end cap from the first end cap. Additionally, embodiments may include triggering a mechanical event to force the second end cap from the first end cap.

Abstract: To provide an aqueous polytetrafluoroethylene (PTFE) emulsion which does not substantially contain ammonium perfluorooctanoate, and which is obtained by emulsion polymerization. Further, to provide a PTFE fine powder which is obtained from the aqueous PTFE emulsion and is excellent in a paste extrusion processability, and a porous material. An aqueous polytetrafluoroethylene emulsion obtained by carrying out emulsion polymerization of tetrafluoroethylene alone or together with another copolymerizable monomer in an aqueous medium, wherein a fluorinated emulsifier of the formula (1): XCF2CF2(O)mCF2CF2OCF2COOA wherein X is a hydrogen atom or a fluorine atom, A is a hydrogen atom, an alkali metal or NH4, and m is an integer of 0 or 1, is used in an amount of from 1,500 to 20,000 ppm, based on the final yield of polytetrafluoroethylene.

Abstract: A process for the production of extruded sheets of expanded polystyrene, which only uses expanding agents with low environmental impact, comprising the steps of: a) heating polystyrene or a mixture composed of polystyrene and at least one component selected from the group consisting flame retardants, coloring agents, plasticizers, heat stabilizers and lubricants at a temperature in the range of 180-2500 C thus obtaining a polymer melt, which is subjected to homogenization; b) adding to the polymer melt a mixture of expanding agents comprising carbon dioxide and water; c) homogenizing the polymer melt including said expanding agents; d) homogeneously cooling the polymer melt to a temperature lower than or equal to 1400 C; e) extruding the cooled polymer melt through a die to obtain an expanded polystyrene sheet.

Abstract: Styrenic polymer foams, especially expanded and/or extruded styrenic polymer foams, are flame retarded by use of one or more flame retardant additives.

Abstract: A polyurethane foam and a resin composition that may be used to form the polyurethane foam is provided. The resin composition comprises a first ethylene diamine-based polyol having about 100% ethylene oxide capping present in an amount of from 0.5 to 8 parts by weight based on 100 parts by weight of the resin composition, a second polyol, and a physical blowing agent. The polyurethane foam comprises the reaction product of an isocyanate component and the resin composition. A method of forming the polyurethane foam on a substrate, comprising the steps of combining the isocyanate component, the first ethylene diamine-based polyol having about 100% ethylene oxide capping, the second polyol, and the physical blowing agent to form a polyurethane composition is also provided. The polyurethane composition is applied onto the substrate at an ambient temperature of 0 C or lower to form the polyurethane foam.

Abstract: The present invention provides a fixing medium suited for fixing biological substances, a medium processing method and a continuous medium processing device. The continuous medium processing device of this invention comprises: a feeding mechanism to run a continuous medium longitudinally along a predetermined travel path; one or more containers installed along the travel path and containing liquids which are to be brought into contact with the continuous medium; gaps provided in each of the containers on the travel path so that the continuous medium can run through the containers; and a liquid leakage prevention unit provided to the containers to prevent possible leakage of the liquids from the gaps.

Abstract: The invention provides a process for producing a polymer mixture, which process is characterized in that nanoscale agglomerates of dendritic polymers having a molar mass of between 400 and 100 000 g/mol are formed by lowering the temperature to below the upper critical solution temperature or raising the temperature to above the lower critical solution temperature of the system in a polymer matrix, and the system is converted into the solid aggregate state by polymerization, temperature change, UV curing, pressure lowering, heat treatment or evaporation of volatile components of the system.

Abstract: The invention relates to radiation-curable formulations which contain adhesion promoters containing phosphoric acid and which in the cured state afford a particular degree of corrosion control for metallic substrates, and to a process for preparing them.

Abstract: Inks are disclosed which are used in ink-jet printing. The inks are cured by ultraviolet radiation, preferably free radical initiation. The inks contain a (meth)acryate monomer, an ?,?-unsaturated ether monomer and a photoinitiator. The inks exhibit a low viscosity and give tough printed images after curing.

Abstract: A photopolymerizable composition including a cationically polymerizable compound and a cation generating agent represented by formula (1): D-L-A ??Formula (1) wherein D represents a light absorption part that shows an absorption having an absorption coefficient of 1000 or more in a wavelength range of 300 nm or longer; A represents an active part which interacts with the light absorption part D to generate a cation when the light absorption part D is excited by light; and L represents a linking group which links the light absorption part D with the active part A.

Abstract: To provide such a base multiplying agent capable of being used for crosslinking reaction, for example of a epoxy compound and the like, that generates another base by action of a base, and can efficiently perform base multiplying reaction, and a base-reactive curable composition using the base multiplying agent. The base generating agent of the invention is represented by the following formula (1): (In the formula (1), X represents a hydrogen atom, a substituted alkyl group or an unsubstituted alkyl group; Y represents a substituted or unsubstituted alkylene chain; and n represents an integer of from 1 to 4.

Abstract: A process for producing a cured coating is provided that includes a step of forming on a substrate a layer of a curable composition that includes at least one compound represented by Formula (I) and a step of curing the layer of the curable composition by irradiating with an electron beam. In Formula (I), Q1 denotes a cyano group or a —COX2 group, X1 denotes a hydrogen atom, organic residue, or polymer chain bonded to carbon atom CA via a heteroatom, or a halogen atom, X2 denotes a hydrogen atom, organic residue, or polymer chain bonded to the carbonyl group via a heteroatom, or a halogen atom, Ra and Rb independently denote a hydrogen atom, a halogen atom, a cyano group, or an organic residue, and X1 and X2, Ra and Rb, and X1 and Ra or Rb may be bonded to each other to form a cyclic structure. There is also provided an electron beam-curable composition that includes a compound represented by Formula (I).

Abstract: The invention relates to novel sulfur-containing (meth)acrylic monomers and compositions thereof characterized by a high refractive index, for optical and industrial applications. The invention also relates to a method for preparing high refractive index polymeric materials and more specifically to a method for formation of ultraviolet cast optical lenses and compositions thereof comprising the sulfur-containing (meth)acrylic monomers.

Abstract: The invention relates to a process for the production of water-soluble or water-swellable polymers having a low content of residual monomers, particularly on the basis of acrylic acid and/or acrylamide and at least one additional water-soluble comonomer, in which process a monomer solution in a polymerizing state is treated with electromagnetic radiation at the earliest after reaching the maximum temperature of polymerization, and the gel obtained is subsequently crushed and dried, and it also relates to the water-soluble or water-swellable polymers as such, which can be obtained according to said process, to their use in the hygiene industry, packaging industry, in the agrarian technology or in agriculture and horticulture, in the cable industry and information technology, in the food industry, papermaking industry, and to their use as flocculation aids and as drilling fluid in petroleum production.

Abstract: A subject-matter of the invention is an impression material with at least one compound with at least two alkenyl groups as component (a), at least one compound with at least one chelating group as component (b), at least one organohydropolysiloxane as component (c), at least one hydrosilylation catalyst as component (d) and at least one compound with a chelatable metal atom as component (e), the chelating group of the component (b) exhibiting no reactive groups which can react with the component (c) and/or the component (d). The invention achieves a long storage stability.

Abstract: The invention relates to an initiator comprising at least one structural element characterized by the following formula (I) wherein X? is a non or low coordinating anion, R1, R2, R3, R4 are independently linear, cyclic or branched C1-C20 alkyl or alkylene groups, wherein one or more of the methylene groups contained in the alkyl or alkylene group can be substituted by —CO—, —CONH—, —CON(CH3)—, —S— and/or —O—, and wherein R1, R2, R3 and/or R4 can act as a bridging element connecting two or more structural elements. The invention is also related to a process of producing the initiator and to a curable composition comprising the initiator, a process for producing the curable composition a kit comprising a cationically curable composition and the inventive initiator and the use of the initiator or the curable composition comprising the initiator for various applications, especially in the dental field.